Open access
Sep 2026
Hierarchical Composite Endpoints for Dose Optimization in Early Phase Oncology Trials
A novel benefit–risk assessment framework for DO in early‐phase oncology trials, utilizing hierarchical composite endpoints (HCEs), which extends the HCE method to incorporate pharmacokinetic data through a probabilistic index model, allowing drug exposure to support dose selection.
Yu-Xiang Wu, Xiao-Han Guo, Ray Li et al.
· Pharmaceutical statistics · 0 citations